ClinicalTrials.Veeva

Menu

A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder

Astellas logo

Astellas

Status and phase

Completed
Phase 3

Conditions

Overactive Bladder

Treatments

Drug: Solifenacin succinate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00189800
90502/KOoTD01

Details and patient eligibility

About

The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Symptoms of overactive bladder
  • Must be able to complete the micturition diary

Exclusion criteria

  • Pregnant or lactating
  • Clinically significant outflow obstruction
  • Significant post void residual urine
  • Significant stress incontinence
  • Urinary tract infection
  • Chronic inflammation
  • Bladder stones
  • Previous pelvic radiation therapy
  • Previous or current malignant disease of the pelvic organs
  • Uncontrolled narrow angle glaucoma
  • Urinary or gastric retention
  • Electrostimulation therapy
  • Bladder training
  • Diabetic neuropathy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems